Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 1
2009 4
2010 11
2011 15
2012 10
2013 13
2014 12
2015 15
2016 21
2017 19
2018 26
2019 29
2020 26
2021 40
2022 30
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB, Jegede OA, Haas NB, Mcdermott DF, Bilen MA, Stein M, Sosman J, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Einstein D, Catalano PJ, Hammers H, Regan MM. Atkins MB, et al. J Immunother Cancer. 2024 Apr 11;12(4):e008293. doi: 10.1136/jitc-2023-008293. J Immunother Cancer. 2024. PMID: 38604810 Free PMC article. Clinical Trial.
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, Miklosi AG, Johal H, Bastos RN, Huang K, Ficial M, Laimon YN, Signoretti S, Zhong Z, Hoang SM, Kastrunes GM, Grimaud M, Fayed A, Yuan HC, Nguyen QD, Thai T, Ivanova EV, Paweletz CP, Wu MR, Choueiri TK, Wee JO, Freeman GJ, Barbie DA, Marasco WA. Wang Y, et al. Mol Cancer. 2024 Mar 16;23(1):56. doi: 10.1186/s12943-024-01952-w. Mol Cancer. 2024. PMID: 38491381 Free PMC article.
Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model.
Wang Y, Cho JW, Kastrunes G, Buck A, Razimbaud C, Culhane AC, Sun J, Braun DA, Choueiri TK, Wu CJ, Jones K, Nguyen QD, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman GJ, Hemberg M, Marasco WA. Wang Y, et al. iScience. 2024 Jan 15;27(2):108879. doi: 10.1016/j.isci.2024.108879. eCollection 2024 Feb 16. iScience. 2024. PMID: 38327771 Free PMC article.
Integrative genotyping of cancer and immune phenotypes by long-read sequencing.
Penter L, Borji M, Nagler A, Lyu H, Lu WS, Cieri N, Maurer K, Oliveira G, Al'Khafaji AM, Garimella KV, Li S, Neuberg DS, Ritz J, Soiffer RJ, Garcia JS, Livak KJ, Wu CJ. Penter L, et al. Nat Commun. 2024 Jan 2;15(1):32. doi: 10.1038/s41467-023-44137-7. Nat Commun. 2024. PMID: 38167262 Free PMC article.
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
Denize T, Jegede OA, Matar S, El Ahmar N, West DJ, Walton E, Bagheri AS, Savla V, Nabil Laimon Y, Gupta S, Vemula SV, Braun DA, Burke KP, Catalano PJ, Freeman GJ, Motzer RJ, Atkins MB, McDermott DF, Sharpe AH, Choueiri TK, Signoretti S. Denize T, et al. Clin Cancer Res. 2024 Feb 16;30(4):803-813. doi: 10.1158/1078-0432.CCR-23-2274. Clin Cancer Res. 2024. PMID: 38060202
Regulation of HHLA2 expression in kidney cancer and myeloid cells.
Shigemura T, Perrot N, Huang Z, Bhatt RS, Sheshdeh AB, Ahmar NE, Ghandour F, Signoretti S, McDermott DF, Freeman GJ, Mahoney KM. Shigemura T, et al. BMC Cancer. 2023 Oct 27;23(1):1039. doi: 10.1186/s12885-023-11496-9. BMC Cancer. 2023. PMID: 37891555 Free PMC article.
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Oya M, Albiges L, Aizawa M, Umeyama Y, Wang J, di Pietro A, Schmidinger M. Tomita Y, et al. ESMO Open. 2023 Dec;8(6):102034. doi: 10.1016/j.esmoop.2023.102034. Epub 2023 Oct 20. ESMO Open. 2023. PMID: 37866029 Free PMC article.
Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.
Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, Zhang T, Song W, Xiao X, Sun Y, Xiong W, Shi J, Dai P, Xiang B, Duan H, Yan X, Wu F, Zhang WC, Lin D, Hu H, Zhang H, Slack FJ, He HH, Freeman GJ, Wei W, Zhang J. Yu H, et al. Cell Chem Biol. 2024 Apr 18;31(4):776-791.e7. doi: 10.1016/j.chembiol.2023.09.001. Epub 2023 Sep 25. Cell Chem Biol. 2024. PMID: 37751743
277 results